Influenza virus intracellular replication dynamics, release kinetics, and particle morphology during propagation in MDCK cells by unknown
APPLIED MICROBIAL AND CELL PHYSIOLOGY
Influenza virus intracellular replication dynamics, release
kinetics, and particle morphology during propagation in MDCK
cells
Timo Frensing1,2 & Sascha Y. Kupke1 & Mandy Bachmann1 & Susanne Fritzsche1 &
Lili E. Gallo-Ramirez1 & Udo Reichl1,2
Received: 27 January 2016 /Revised: 3 April 2016 /Accepted: 11 April 2016 /Published online: 29 April 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Influenza viruses are respiratory pathogens and can
cause severe disease. The best protection against influenza is
provided by annual vaccination. These vaccines are produced
in embryonated chicken eggs or using continuous animal cell
lines. The latter processes are more flexible and scalable to
meet the growing global demand. However, virus production
in cell cultures is more expensive. Hence, further research is
needed to make these processes more cost-effective and ro-
bust. We studied influenza virus replication dynamics to iden-
tify factors that limit the virus yield in adherent Madin-Darby
canine kidney (MDCK) cells. The cell cycle stage of MDCK
cells had no impact during early infection. Yet, our results
showed that the influenza virus RNA synthesis levels out al-
ready 4 h post infection at a time when viral genome segments
are exported from the nucleus. Nevertheless, virus release oc-
curred at a constant rate in the following 16 h. Thereafter, the
production of infectious viruses dramatically decreased, but
cells continued to produce particles contributing to the hem-
agglutination (HA) titer. The majority of these particles from
the late phase of infection were deformed or broken virus
particles as well as large membranous structures decorated
with viral surface proteins. These changes in particle charac-
teristics and morphology need to be considered for the opti-
mization of influenza virus production and vaccine purifica-
tion steps. Moreover, our data suggest that in order to achieve
higher cell-specific yields, a prolonged phase of viral RNA
synthesis and/or a more efficient release of influenza virus
particles is required.
Keywords Influenza virus . Vaccine production . Virus
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Introduction
Influenza is a contagious respiratory disease caused by
influenza virus infections. Annually, influenza A and B
viruses account for three to five million cases of severe
illness and between 250,000 and 500,000 people decease
due to these infections worldwide (estimates of the World
Health Organization (WHO), Fact sheet Influenza No. 211,
March 2014). Especially very young children (< 2 years),
older people (> 65 years), and patients with underlying
medical conditions such as chronic and metabolic diseases
or a weakened immune system are at high risk to develop
flu-related complications. Despite numerous attempts to
develop drugs for the treatment of severe influenza infec-
tions, only two classes of antiviral drugs have been li-
censed so far. However, due to their frequent use, resistant
influenza virus variants have already emerged. Thus, the
best protection against influenza is annual vaccination.
Nowadays, cell culture-based influenza vaccine production
has become an important alternative to the conventional
manufacturing process in embryonated chicken eggs.
Compared to egg-based processes, cell culture technology
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has significant advantages such as higher flexibility and
scalability since it is independent from the timely supply
and laborious handling of embryonated eggs. In addition,
these processes are not vulnerable to the threat of avian
influenza viruses that can kill laying flocks. Moreover, ste-
rility can easier be maintained in cell culture (reviewed by
Audsley and Tannock (2008)). Recently, the first recombi-
nant influenza vaccine produced in insect cells received
approval (Buckland et al. 2014). Other vaccine manufac-
turers propagate influenza viruses in MDCK cells or
African green monkey kidney (Vero) cells. However, a
thorough understanding of the viral replication cycle,
virus-host cell interactions, and virus spreading in cell pop-
ulations is crucial to further optimize vaccine production in
these cells.
Influenza viruses belong to the family ofOrthomyxoviridae.
They are enveloped viruses with a segmented single-stranded
RNA genome of negative polarity. The genome of influenza A
viruses consists of eight segments encoding for 10 major pro-
teins and additional seven accessory polypeptides (reviewed by
Vasin et al. (2014)). Each genomic viral RNA (vRNA) segment
is present as a viral ribonucleoprotein (vRNP) complex contain-
ing the tripartite RNA-dependent RNA polymerase (RdRP)
complex and the vRNA encapsidated by multiple monomers
of the viral nucleoprotein (NP). The RdRP accomplishes both
transcription and replication of the viral genome, which takes
place in the nucleus of infected cells. While transcription is
directly initiated after the nuclear import of vRNPs, replication
can only proceed in the presence of newly synthesized viral
proteins. It has been reported that newly produced RdRPs and
NPs stabilize the replication intermediates, i.e., complementary
RNAs (cRNAs), forming cRNPs which serve as templates for
the synthesis of progeny vRNAs (reviewed by Elton et al.
(2006)). At later stages of the infection cycle, the matrix protein
1 (M1) and the nuclear export protein (NEP; also known as
non-structural protein 2 (NS2)) bind to vRNPs which leads to
their nuclear export and to the termination of viral RNA syn-
thesis (reviewed by Cros and Palese (2003)). Subsequently,
viral genomes and proteins are transported to the plasma mem-
brane where virus assembly and budding take place (reviewed
by Bouvier and Palese (2008)). Activation of signal transduc-
tion pathways and accumulation of viral components in the
course of an infection lead to the induction of programmed cell
death (apoptosis). On the one hand, virus propagation can
be impaired when apoptosis is induced early during infec-
tion before virus replication has reached its full magni-
tude. On the other hand, apoptosis at later time points
seems to support the release of virions and therefore be-
comes pro-viral (reviewed by Herold et al. (2012)). Many
details of the influenza virus life cycle have already been
unraveled, but still little is known about the relative im-
portance of all steps involved and how their interplay
determines the virus titer in cell cultures.
To identify possible bottlenecks for the production of in-
fluenza viruses on the molecular level, we thoroughly studied
the dynamics of influenza virus replication in adherent
MDCK cells. To this end, we analyzed virus release kinetics
in a single-cycle infection by exchanging the medium in reg-
ular intervals. Using electron microscopy, we compared the
morphology of virus particles from an early phase of the in-
fection with particles from the later stage when almost exclu-
sively noninfectious particles were produced. In addition, we
examined the intracellular dynamics of viral RNA synthesis
and the localization of viral components in the course of an
infection cycle. The latter was done by imaging cytometry that
combines the throughput and sensitivity of conventional flow
cytometry with the spatial resolution of fluorescence micros-
copy. Finally, we performed an infection at low multiplicity of
infection (MOI) to investigate if cells in a particular cell cycle




Adherent MDCK cells (ECACC, No. 84121903) were culti-
vated in Glasgow’s minimum essential medium (GMEM),
supplemented with 10 % (v/v) fetal calf serum (FCS) and
1 % (v/v) peptone at 37 °C in a 5 % CO2 atmosphere. For
infection experiments, we used serum-free infection medium
comprised of GMEM, 1 % (v/v) peptone and trypsin (Sigma-
Aldrich, # T7409) was applied at a concentration of 5 BAEE
U/mL (4.5 μg/mL). Influenza virus strain A/Puerto Rico/8/34
(PR8) was obtained from the National Institute for Biological
Standards and Control (No. 06/114). The seed virus titer was
determined by standard plaque assay (1.76 × 108 plaque
forming units (PFU) per mL).
Virus infections
For single-cycle experiments confluent cells in T75 flasks
were washed twice with phosphate-buffered saline (PBS)
and afterwards infected at an MOI of 10 PFU per cell in
3 mL of infection media for 1 h. During the incubation at
37 °C in a 5 % CO2 atmosphere, flasks were rocked every
20 min to keep the monolayer moist and to distribute viruses
evenly. Thereafter, the inoculum was removed, cells were
washed twice with PBS, and 13 mL of infection media were
added to the flasks. At every sampling time point, one flask
was used to analyze the intracellular infection dynamics by
quantitative reverse transcription PCR (RT-qPCR) and imag-
ing flow cytometry.
To study virus release kinetics, only 5 mL of virus infection
media were added to one flask. The supernatant of this flask
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was harvested every 4 h. To this end, the flask was rocked to
swirl up detached cells and the supernatant was harvested.
Five milliliters of infection media was used to wash the cell
monolayer and was then combinedwith the supernatant. Fresh
infection media (5 mL) was added to the flask that was
returned to the incubator. We then determined the cell number
in the supernatant (i.e., detached cells) using a Vi-CELL™
(Beckman Coulter), the remaining sample was centrifuged at
300×g for 10 min at 4 °C. Aliquots of supernatants were
stored at −80 °C until virus titration. Four flasks containing
13 mL of infection media served as controls to determine the
virus titer without medium exchange and to obtain the cell
count of adherent cells.
In addition, low MOI infections were performed to inves-
tigate if cells in a certain cell cycle stage become preferentially
infected. One day before infection, 2.5 × 106 MDCK cells
were seeded in T25 flasks and incubated at 37 °C and 5 %
CO2 for 14 h. Thereafter, the cells were mock-infected or
infected with influenza virus PR8 at an MOI of 0.1 in 1 mL
infection medium. The inoculum was removed after 45 min,
cells were washed once with PBS, and cells were incubated at
37 °C and 5 % CO2 in 3 mL GMEM supplemented with 10 %
(v/v) FCS (without trypsin to reduce secondary infections). At
each sampling time point, one T25 flask was harvested.
Virus quantification
Virus titers were determined by the hemagglutination assay
(Kalbfuss et al. 2008) and the 50 % tissue culture infective
dose (TCID50) assay (Genzel and Udo 2007). Titers of the
HA assay were expressed as log10 HA units per test vol-
ume (log10 HAU/100 μL). Total virus particle concentra-
tion (cvirus [virions/mL]) was determined, assuming that
agglutination occurs up to a dilution in which the amount
of virus particles equals the amount of erythrocytes
(Werner and Schlesinger 1954). Thus, the calculation was
based on HA titer and cell concentration of the erythrocyte
suspension (2 × 107 cells/mL).





Cell-specific, cumulative virus release was assessed by re-
ferring to the maximum cell count obtained in each
experiment.
Sampling for RT-qPCR and imaging flow cytometry
Infected cells in T75 flasks were rocked to swirl up detached
cells and the supernatant was harvested. Detached cells were
separated from the supernatant by centrifugation. Remaining
adherent cells in T75 flasks were trypsinized and afterwards
combined with the detached cells from the previous step. For
this cell suspension, we then determined cell count and via-
bility (by trypan blue staining) using a Vi-CELL™ (Beckman
Coulter). An aliquot of 1 × 106 cells was centrifuged and cell
pellets were lysed with 350 μL of lysis buffer RA1 (Macherey
Nagel) containing 1 % (v/v) β-mercaptoethanol. Lysates were
stored at −80 °C until RNA purification according to the man-
ufacturer’s instructions (“NucleoSpin RNA” from Macherey
Nagel). The remaining cell suspension was fixed with para-
formaldehyde at a final concentration of 1 % (w/v) and ali-
quots of 1 × 106 cells were stored in 70 % ethanol at −20 °C
until staining for imaging flow cytometry. For infection exper-
iments at low MOI, 2 × 106 cells were collected and fixed for
the analysis by imaging cytometry.
In vitro synthesis of RNA reference standards
For absolute quantification of intracellular v/c/messenger
RNA (mRNA) concentration of segment 5, corresponding
RNA reference standards were synthesized by in vitro tran-
scription. For this, plasmids carrying the full sequence of v/c/
mRNAwere used as template for conventional PCR. The T7
promotor sequence was introduced by primers (Online
Resource, Tab. S1). PCR conditions were as followed: dena-
turation at 98 °C for 3 min, 35 cycles at 98 °C for 25 s, 53 °C
for 45 s, and 72 °C for 90 s and final elongation at 72 °C for
10 min. Thereafter, PCR products were purified (InnuPrep
PCR pure Kit, Analytik Jena) and used for in vitro transcrip-
tion (TranscriptAid T7 High Yield Transcription Kit, Thermo
Fisher Scientific) according to the manufacturer’s instructions.
Finally, RNA standards were purified (NucleoSpin RNA
Clean-up Kit, Macherey & Nagel) and stored at −80 °C.
Real-time RT-qPCR
In order to quantify intracellular levels of v/c/mRNA, we used
a real-time RT-qPCR approach with polarity- and gene-
specific tagged primers in the RT reaction. Primer sequences
are listed in supplementary table S2 (Online Resource). In
brief, 1 μL of RNAwas mixed with 1 μL primer (1 μM for
v/cRNA; 10 μM for mRNA), 1 μL dNTPs (10 mM each), and
11.5 μL RNase/DNase-free water. Thereafter, the mixture was
incubated at 65 °C for 5 min and subsequently cooled to 42 °C
for mRNA and 55 °C for c/vRNA. The reaction mixture (4μL
5X Reaction Buffer, 0.5 μL Maxima H-Minus Reverse
Transcriptase (200 U/μL, Thermo Scientific), 0.5 μL
RiboLock™ RNase Inhibitor (40 U/μL, Thermo Scientific),
0.5 μL RNase/DNase-free water) was pre-warmed at 42 °C
for mRNA and 55 °C for c/vRNA for 1 min, added to the
RNA reaction mix and incubated at 60 °C for 30 min before
a final RT inactivation step at 85 °C for 5 min was carried out.
In addition, RT reactions were performed with 10-fold serial
dilutions of the corresponding reference standard (5 ng to
5 × 10−7 ng). Thereby, 350 ng of total MDCKRNAwas added
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to mimic intracellular conditions within the standard samples.
Finally, complementary DNA (cDNA) was filled up to
100 μL with RNase/DNase-free water and stored at −20 °C
until use. Viral RNA concentrations were determined with the
“Rotor-Gene SYBR Green PCR Kit” (QIAGEN) by real-time
RT-qPCR. To this end, 4 μL of cDNA, 1 μL primer set
(Online Resource, Tab. S3) and 5 μL of reaction mixture were
combined and analyzed with a Rotor-Gene Q real-time PCR
cycler (QIAGEN). The temperature profile included denatur-
ation at 95 °C for 5 min, amplification in two steps at 95 °C for
10 s, and 62 °C for 20 s and a melting curve from 65 to 90 °C.
To calculate viral RNA concentration, Ct values obtained for
the RNA reference standards were plotted against log10 num-
bers of viral molecules resulting in a linear calibration curve.
The number of viral RNA molecules (nmolecules) was deter-
mined based on quantity of the template (mtemplate [ng]), frag-
ment length (N(bases) [bp]), average mass of one base (k = 340
[Da/bp] and the Avogadro constant (NA[mol
−1]).
n moleculesð Þ ¼
mtemplate
k  N basesð Þ  N−1A  109
To calculate the number of molecules per cell (SQsample
[molecules/cell]), the slope (m) and the y-intercept (b) of the
calibration curve, the coefficient for dilution of RT reaction
(FRT) and the volume of RNA eluate (Veluate [μL]) were con-




mð Þ  FRT  V eluate
ncells
Imaging flow cytometry
Stored samples were centrifuged for 10min at 300×g and 4 °C
and the supernatant was discarded. Then, cells were washed in
4 mL fluorescence-activated cell sorting (FACS) buffer (PBS,
2 % (w/v) glycine, 0.1 % (w/v) bovine serum albumin (BSA))
and centrifuged as before. Subsequently, cells were blocked in
150 μL FACS buffer containing 1.1 % (w/v) BSA for 1 h on
ice. After centrifugation for 10 min at 300×g and 4 °C, cell
pellets were resuspended in 100 μL antibody solution. All
antibody incubations were performed at 37 °C for 1 h in the
dark. The monoclonal mouse anti-NP antibody mAb61A5 (a
kind gift from Fumitaka Momose) was used at a dilution of
1:500. This antibody preferentially binds to NP in the confor-
mation inherent to the vRNP complex (Momose et al. 2007).
Following incubation, the cells were washed three times with
FACS buffer. Secondary antibody staining was performed
using Alexa Fluor 647-conjugated polyclonal goat anti-
mouse antibody (LifeTechnologies, #A21235) at a dilution
of 1:500. Subsequently, cells were washed three times with
wash buffer and 4′,6-diamidino-2-phenylindole (DAPI) was
used for nuclear staining.
The immunostaining of M1 was performed using a FITC-
conjugated monoclonal mouse anti-M1 antibody (AbD
serotec, #MCA401FX) at a dilution of 1:100. After incubation
and three washing steps, cells were resuspended in 40 μL of
wash buffer. RNA degradation was conducted by adding 5 μL
PureLink™ RNase A (20 mg/mL, life technologies). For nu-
clear staining, 0.5 μL of 7-AAD (Millipore) were added
followed by an incubation for 30 min at room temperature in
the dark.
Using the ImageStream X Mark II (Amnis, EMD
Millipore) 10,000 single cells per sample (debris and cell
doublets were excluded) were analyzed using ×40 or ×60
objective lenses. For infection experiments at low MOI, up
to 300,000 single cells were measured. The 375 and
642 nm lasers were utilized for the excitation of the
DAPI- and vRNP-stained samples. Channels 1 (CH1) and
5 (CH5) were acquired along with the bright field (BF)
imagery on channel 6 (CH6). For the M1- and 7-AAD-
stained samples, the 488 and 642 nm lasers were utilized
for excitation and signal acquisition was conducted in
channels 2 (CH2) and 5 (CH5) along with the BF imagery
on channel 1 (CH1). Before acquisition, the laser power
was adjusted to yield a “raw max pixel” feature value be-
tween 200 and 1500 of the single-stained positive controls.
One thousand cells of these samples were acquired for
compensation with the respective compensation settings.
Image analysis
IDEAS software (version 6.1) was used for image analysis.
Compensation matrices were generated using the correspond-
ing compensation files. Only single cells in-focus were select-
ed for analysis. Segmentation masks for M1- and vRNP-
positive cells were generated based on mock-infected
samples.
Nuclear localization of vRNPs as well as M1 was
assessed by calculating fractions of fluorescence intensity
(FI) of vRNP or M1 signal co-localized with the DAPI or
7-AAD signal, respectively. For vRNP analysis, the mask
“nucleus” was generated using the function “morphology”
(on CH1 imagery) and the mask “whole cell” was gener-
ated using the function “object” (on CH6). Features termed
“intensity CH5 nucleus” and “intensity CH5 whole cell”
were created by utilizing feature “intensity” (of CH5) with-
in mask nucleus and whole cell, respectively. The com-
bined feature “FI in nucleus” was generated with following
definition: intensity CH5 nucleus/intensity CH5 whole
cell. CH1- and Ch5-double positive cells were plotted on
histograms using this feature. Mean values, multiplied by
100, yielded the fraction of FI in the nucleus (%). The M1
analysis was performed using the same procedure, but tak-
ing the corresponding channels into account.
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Apoptotic cells were quantified based on chromatin
condensation and nuclear fragmentation (leading to an in-
crease in the intensity and a decrease in the area of the
nuclear signal) as well as cell shrinkage (leading to higher
BF contrast) as described before (Maguire et al. 2011). For
this, the mask “threshold 50 % CH1” was generated using
the function “threshold” on CH1 imagery (parameter “in-
tensity percentage” at 50 %). A feature called “area thresh-
old 50 % CH1” was generated by using feature “area” on
mask area threshold 50 % CH1. Distinct populations of
apoptotic cells were differentiated from non-apoptotic cells
by plotting focused, single cells on feature “contrast CH6”
against area threshold 50 % CH1.
The gates for cell cycle phases G0/G1, S, and G2/M were
defined in a dot plot of DAPI intensity vs. DAPI signal
area (Online Resource, Fig. S1). Infected cells were iden-
tified using a Max Pixel histogram of mock-infected sam-
ples for each time point.
nsTEM analysis
An imaging service using negative stain transmission elec-
tron microscopy (nsTEM) was performed by Vironova
(Stockholm, Sweden). Briefly, 3 μL of the sample
(inactivated by β-propiolactone) were applied on glow
discharged carbon-coated 400 mesh copper grids using
the direct drop procedure. Samples were incubated for ap-
proximately 30 s, blotted off using a filter paper, washed
with MilliQ water and finally negatively stained using 2 %
uranyl acetate. After blotting off the stain, the grid was
allowed to air dry. Grids were imaged using a Tecnai G2
Spirit BioTWIN (FEI) electron microscope operated at an
accelerating voltage of 100 kV. Images were acquired
using a 2 k × 2 k Veleta CCD camera (Olympus Soft
Imaging System, OSiS).
For each sample, five remotely located grid positions,
with good sample embedding, were selected. At each po-
sition, by traversing the grid at 68 k magnification, a total
of 20 images were acquired. Image data was collected, as
soon as one or more particles were detected in the field of
view. Particles were subsequently classified as intact, de-
formed, or broken, and large membranous by manual im-
age analysis. Thereby, spherical and close to spherical
particles approximately 80–140 nm in diameter with
well-resolved surface spike proteins were classified as
intact particles. Particles that displayed major perturba-
tions and even rupture of the membrane were classified
as deformed or broken particles. Moreover, particles that
had the characteristic appearance of lipid membranes
(folded structures, commonly with bright edges and a
denser interior) and were larger than the typical influenza
virion in size (200–700 nm) were classified as large
membranous particles.
Results
Production dynamics of influenza viruses in MDCK cells
To study thoroughly the dynamics of influenza virus replica-
tion in cell lines used for vaccine manufacturing, we infected
MDCK cells with the influenza strain A/Puerto Rico/8/34. In
contrast to vaccine production processes which typically use a
low MOI, we performed the infection at an MOI of 10 PFU
per cell. This high MOI ensures that the complete cell popu-
lation becomes rapidly infected and consequently enables the
detailed analysis of a synchronized single-cycle infection. We
investigated the dynamics of virus production by harvesting
the complete supernatant of the cells and subsequent addition
of fresh medium every 4 h. All samples were subjected to the
TCID50 assay and the HA assay to determine the concentra-
tion of infectious and total virus particles, respectively.
Cumulative growth curves were generated by adding up
the titers of every successive sampling interval in the
course of the infection experiment (Fig. 1a, b). To check
whether the replacement of the medium every 4 h had an
impact on the infection process, cells were infected under
the same conditions but incubated without medium ex-
change for 12, 24 and 36 h. No significant differences in
the total virus particle counts were observed between cells
with and without medium exchange demonstrating that the
experimental procedure did not affect the influenza virus
propagation. Under both conditions, the same final HA
titer was reached which corresponded to approximately
15,000 particles per cell (Fig 1a). In contrast, infectious
virus particles reached lower final yields of about 200
virions per cell (Fig. 1b). When we calculated the cell-
specific virus particle production per hour, it became ob-
vious that the rate of virus release for both infectious and
total virus particles reached its maximum already in the
sampling interval between 4 and 8 h post infection (hpi)
(Fig. 1c). In the following 12 h, the virus release occurred
at a rather constant rate and the ratio of infectious to total
virus particles was more or less stable. However, the pro-
duction of infectious particles started to decline already
between 16 and 20 hpi and 95 % of the final infectious
virus yield was reached at 20 hpi (first dashed line). In
contrast, a significant drop in the release of total particles
detected by the HA assay occurred after 28 hpi when 95 %
of the final total virus particle count was reached (second
dashed line). In the early phase (before 20 hpi), 2 to 4 %
of the released influenza virus particles were infectious. At
later stages of the infection, cells almost exclusively pro-
duced noninfectious particles (below 0.3 % infectious par-
ticles). In addition, we determined cell counts and the cell
viability in the time course of the single-cycle infection.
Simultaneous to the decrease in the production of infec-
tious particles, the adherent MDCK cells started to detach
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from the bottom of the cell culture flask and the viability
measured by trypan blue staining started to decrease
(Fig. 1d). Most of the cells were found in the supernatant
at 28 hpi when the production of total virus particles also
declined. Taken together, our thorough analysis of the
single-cycle infection experiment revealed that progeny
virus particles are released with a rather constant rate for
a relatively long period of time. However, the production
of infectious particles decreased much earlier than the pro-
duction of particles contributing to the HA titer.
Morphology of influenza virus particles from early
and late stages of the infection
Next, we investigated differences between virus particles pro-
duced at early time points compared to late time points when
almost exclusively noninfectious particles were produced. To
this end, particle morphologywas examined by nsTEM. In the
early phase of the infection (between 8 and 12 hpi) most
particles were spherical (Fig. 2a, upper panel). In addition to
these apparently intact virus particles, deformed or broken
particles and large membranous structures were present. The
latter often appeared decorated with viral surface proteins. The
average diameter of 435 particles from the early phase of an
infection was 117 ± 25 nm (data not shown). The proportion
of particles with the different afore mentioned morphologies
was quantified by analyzing 100 nsTEM images of a sample
of an early time frame (8–12 hpi) and 100 images of a sample
representing the time frame 20 to 24 hpi. The particle classi-
fication clearly showed that more than 50 % of the virions
appeared as intact spherical particles at the early sampling
time point (Fig. 2b). In contrast, only about 25 % of the par-
ticles were intact spherical at the later stage between 20 and
24 hpi. At this stage, the majority of particles was deformed or
broken and the amount of large membranous structures also
increased. Thus, the particle characteristics change during the
course of one infection cycle and the morphological analysis
supports the previous observation that less infectious particles
are produced at later stages of the infection (Fig. 1).
Dynamics of the influenza virus RNA synthesis
In order to study the intracellular dynamics of influenza virus
replication, we performed a strand-specific RT-qPCR on infect-
ed cells. This method enables the quantification of all three
influenza virus RNA species, i.e., viral mRNA, cRNA, and
vRNA. We measured the three RNA species of the genome
segment 5, which encodes for the nucleoprotein. For this, ad-
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Fig. 1 Virus production kinetics. MDCK cells were infected with the
influenza virus PR8 at an MOI of 10 PFU per cell. The supernatant was
harvested every 4 h and replaced with fresh media. Infections without
medium exchange (incubated for 12, 24, and 36 h) served as controls. The
number of total virus particles was calculated based on the HA titer and
infectious virions were quantified by the TCID50 assay. Depicted are the
cumulative titers of total (a) and infectious virus particles per cell (b) as
well as the virus release rates per hour (c). The first and the second dashed
lines indicate time points when ≥95 % of the final titer of infectious and
total particles were released, respectively. Control titers (upper panel)
indicate the number of total virions released from infected cells without
medium exchange. d Cell counts and cell viability. The cumulative
numbers of detached cells are depicted. Numbers of adherent cells and
viabilities of all cells (based on trypan blue staining) are derived from
infected cells without medium exchange. Error bars indicate standard
deviation of three independent experiments
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infected with the influenza virus PR8 at an MOI of 10 PFU per
cell. The inoculum was removed after 1 h and fresh medium
was added, but thereafter the medium was not replaced until
cells were harvested. Viral mRNA levels increased directly after
the infection and reached their maximal level around 4 hpi.
Thereafter, viral mRNA levels steadily decreased (Fig. 3a).
The increase of cRNA also occurred directly after the infection.
From 4 hpi onwards, cRNA synthesis leveled out and the
cRNA remained at a relatively low concentration (200 to 500
copies per cell) until the end of our infection experiment
(Fig. 3b). For the vRNA, a higher starting concentration at
0 hpi was detected which is reasonable as infecting virus parti-
cles contain vRNA. In contrast, low levels of viral mRNAwere
detected at 0 hpi which most probably represents a contamina-
tion of the seed virus with viral mRNAs due to cell lysis during
seed virus production. Similar to the synthesis of cRNA, vRNA
levels reached a plateau from 4 hpi onwards, but vRNA con-
centrations were approximately two orders of magnitude higher
than cRNA concentrations. In summary, viral RNA synthesis is
initiated directly after the infection, but levels out already at
4 hpi.
Imaging cytometry of virus-infected cells
Furthermore, we examined the progression of the infection by
imaging cytometry, a method that combines the throughput of
flow cytometry with the spatial resolution of fluorescent mi-
croscopy. Cells were stained using either a combination of
DAPI and an antibody against vRNPs (Fig. 4a) or 7-AAD
together with an antibody against M1 (Fig. 4d). Already
30 min after the high MOI infection, more than 90 % of the
cell population contained vRNPs and within 1 h, almost the
complete cell population was infected (Fig. 4b). At the later
stage of the infection, condensation and fragmentation of the
nucleus (DAPI) was observed (Fig. 4a, right panel). This
staining pattern was used to identify apoptotic cells. The frac-
tion of apoptotic cells started to increase between 16 and
20 hpi and reached its maximum of approximately 77 % at
32 hpi (Fig. 4b). In addition, we investigated the intracellular
localization of vRNPs and M1. Between 30 min to 3 h after
the infection, 70 to 80 % of the fluorescent signal of vRNPs
was found in the nucleus (Fig. 4c). However, between 3 and
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Fig. 2 Virus particle morphology
at early and late stages of virus
production. Cells were infected
with influenza virus PR8 at an
MOI of 10 PFU per cell and
supernatants were harvested and
replenished with fresh medium
every 4 h. Selected samples were
subjected to negative stain
transmission electron microscopy.
a Virus particle morphology.
Representative images of released
particles at early (8–12 hpi) and
late (20–24 hpi) stages of virus
production are shown. Particles
were classified as indicated by
arrows: (I) intact and spherical
with well-resolved surface spike
proteins; (II) deformed or broken
with distinct spike protein-
decorated surface; (III) large
membranous, of which many
appear spike-decorated. Insets
show higher magnifications of
selected particles. Scale bar
indicates 250 nm. b Quantitative
results of particle classification.
Particles of a total of 100 images
per sample (yielding 345 and 314
particles for early and late stages,
respectively) were subjected to
manual classification analysis.
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within the nucleus decreased strongly which indicates a fast
nuclear export of vRNPs. Subsequently, vRNPs were mainly
localized close to the plasmamembrane as indicated by a ring-
like staining pattern of vRNPs between 8 and 36 hpi (Fig. 4a).
In contrast to vRNPs,M1was more evenly distributed and not
predominantly localized in the nucleus at early time points.
Yet, between 3 and 4 hpi, the amount of M1 in the nucleus
slightly increased (Fig. 4c). Due to the fact that the total signal
intensity of M1 increased strongly in the course of the infec-
tion, this slight enrichment of M1 in the nucleus cannot be
inferred easily from individual images (Fig. 4d). However,
the analysis of thousands of cells clearly indicates that
M1 is imported into the nucleus between 3 and 4 hpi while
vRNPs are exported. Both shifts point to active transport
processes. At later stages of the infection, however, the
analysis of the nuclear localization of viral proteins was
biased by the condensation and fragmentation of the nucle-
us caused by the induction of apoptosis. Therefore, the
nuclear localization can be studied reliably only up to
about 16 hpi. Taken together, imaging cytometry con-
firmed the rapid synchronized infection of the complete
cell population and showed that a strong nuclear export
of viral genomes occurred already between 3 and 4 hpi.
Impact of cell cycle stage of MDCK cells on the influenza
virus infection
As it was reported that influenza virus infects preferentially
cells in the G1 phase of the cell cycle (Ueda et al. 2013) and
that G0/G1 phase-synchronized cells produce higher virus ti-
ters compared to unsynchronized cells (He et al. 2010), we
studied the impact of the cell cycle on influenza virus infec-
tions of MDCK cells. To this end, we infected MDCK cells
with the influenza virus PR8 at an MOI of 0.1. At this low
MOI, about 10 % of the cell population should become infect-
ed and we wanted to check whether these infected cells were
predominantly in the G1 phase. The infection was performed
for 45 min in serum-free medium containing trypsin.
Subsequently, the inoculum was removed, cells were washed,
and incubated in medium without trypsin but with 10 % FCS
to avoid secondary infections and to reduce the impact of
serum depletion on cell cycle progression. Based on the inten-
sity of the DAPI staining, the cell cycle stage of cells was
determined. In addition, an immunostaining for vRNPs was
used to identify infected cells. As expected, about 10 % of the
cell population were infected and this proportion stayed nearly
constant for 9 h, indicating that almost no secondary infections
occurred (Fig. 5a). Regardless of the cell cycle stage, in each
subpopulation of cells, we found around 10 % infected cells,
showing that cells in different cell cycle stages had a similar
probability to become infected. Hence, we found no evidence
that MDCK cells in a certain cell cycle stage are preferentially
infected. Furthermore, infected MDCK cells showed a similar
cell cycle progression compared to mock-infected cells within
the first 9 hpi (Fig. 5b, c). This indicates that the infection did
not induce a cell cycle arrest in the early phase of the infection.
In summary, for MDCK cells, no impact of the cell cycle stage
on the influenza virus entry was found.
Discussion
For the optimization of cell culture-based influenza vaccine
production, a thorough understanding of the influenza virus
replication cycle and of virus-host cell interactions is crucial to
develop strategies for a rational design of high yield produc-
tion cell lines or vaccine strains. In this study, we analyzed in
detail the influenza virus replication in MDCK cells. To this
end, a high MOI infection was performed to examine a single
round of infection in a synchronously infected cell population.
An immunostaining against vRNPs and the analysis by imag-
ing cytometry confirmed that the complete cell population
was rapidly infected under these conditions (Fig. 4b). The
progeny virus release was investigated by exchanging the
Fig. 3 Dynamics of the intracellular viral RNA synthesis. MDCK cells
were infected with the influenza virus PR8 at an MOI of 10 PFU per cell
and harvested at indicated time points. Viral mRNA (a) as well as cRNA
and vRNA (b) of the influenza virus genome segment 5 were measured
by a strand-specific RT-qPCR. The data shown represent the mean of
three independent experiments and error bars indicate the standard
deviation
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complete supernatant of infected cultures with fresh medium
every 4 h. In doing so, we were able to demonstrate that the
virus release rate reached its maximum already in the sam-
pling interval between 4 and 8 hpi (Fig. 1c). Moreover, we
did not find a burst-like influenza virus production but instead
a constant release of progeny virus particles over a relatively
long period of time. To our knowledge, such a constant influ-
enza virus release has not been reported before. In an early
study, more fluctuations of the virus release have been found
but sampling intervals were not as regular as in our experiment
(Gaush and Smith 1968). Furthermore, we found that the ratio
of infectious to total virus particles was stable during the early
phase of the infection and below a ratio of 1:10 which is
typical for influenza viruses (reviewed by Brooke (2014)).
However, the release of infectious virions decreased approxi-
mately 8 h earlier than the production of particles measured in
an HA assay (Fig. 1). The multitude of these noninfectious
particles in the late phase of the infection (from 20 hpi on-
wards) probably did not result from the degradation of infec-
tious particles since the experimental setup prevents extensive
degradation by the repetitive harvest and the exchange of the
complete culture supernatant every 4 h. Hence, in the late
phase of the infection, cells seem to produce almost exclusive-
ly defective particles or cellular debris decorated with viral
HA proteins, both able to contribute to the HA titer. Indeed,
we found that the proportion of apparently intact spherical
particles decreased in the late phase and more deformed or
broken particles as well as large membranous structures were
detected by electron microscopy (Fig. 2). It has been reported
before that the morphology of noninfectious influenza virus
particles differs from the uniform spherical shape of infectious
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Fig. 4 Imaging cytometry of
virus-infected cells. MDCK cells
were infected with influenza PR8
virus at an MOI of 10 PFU per
cell. At indicated time points,
cells were fixed and stained for
vRNPs and cell nuclei using
DAPI (a) or for M1 and cell
nuclei using 7-AAD (d). a Images
of individual cells at selected time
points after the infection. Each
panel series shows the DAPI,
vRNP, and bright field (BF) signal
of representative cells. b, c
Spatio-temporal analysis of virus
replication. Image analysis was
performed using the IDEAS
software. Diagrams show the
following fractions (%): b
Infected cells (showing a vRNP
signal) and apoptotic cells
(showing nuclear fragmentation);
c vRNPs in the nucleus (based on
the amount of vRNP signal co-
localized with the DAPI signal)
and M1 in the nucleus (based on
the proportion of M1 signal co-
localized with the 7-AAD signal).
d Images of individual cells at
selected time points after the
infection. Each panel series shows
the 7-AAD, M1, and BF signal of
representative cells. First and
second dashed lines indicate time
points when ≥95 % of the final
titer of infectious and total virus
particles were released,
respectively. Error bars indicate
standard deviations of three
independent experiments
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of disintegration (Paucker et al. 1959; Werner and Schlesinger
1954). Yet, these studies used noninfectious particles from
undiluted passaging experiments in which the amount of in-
fectious particles decreases due to the accumulation of so-
called defective interfering particles (DIPs). In contrast, we
observed that the particle morphology already changes in the
course of one single infection cycle. In the late phase of the
infection, cells predominantly produce pleomorphic noninfec-
tious particles and large membranous structures. While DIPs
were detectable throughout our infection experiment at high
MOI, they did not accumulate predominantly in the late phase
of the infection (data not shown). Therefore, it does not seem
likely that DIPs cause the observed changes of the particle
morphology and infectivity in the late phase. Yet, we found
that these changes occurred in the phase when cell viability
dropped, adherent cells started to detach from the bottom of
the cell culture flask (Fig. 1d) and when nuclear fragmentation
indicated apoptosis of infected cells (Fig. 4b). More research
is required to understand why and when cells lose their capac-
ity to produce infectious spherical particles and if this is asso-
ciated with the progression of apoptosis. However, our results
are in line with a previous report from our group showing that
infectious particles are produced predominantly in the early
phase during influenza vaccine production in bioreactors and
that total virus release is terminated by cell death (Schulze-
Horsel et al. 2009).
Changes of the particle morphology and infectivity in the
late phase of the infection might have important consequences
for vaccine manufacturing. Pleomorphic particles could be
related to losses during purification steps such as size exclu-
sion or affinity chromatography due to their variable shape
and size. In addition, it has been reported by others that pleo-
morphic noninfectious particles contain reduced amounts of
HA and vRNPs compared to infectious particles that are uni-
formly spherical (Paucker et al. 1959). Accordingly, noninfec-
tious particles might yield lower antigen concentrations for
split vaccines if they possess a reduced HA content. In addi-
tion, the accumulation of large membranous structures deco-
rated with viral surface proteins might be a challenge for
downstream purification regarding contaminant levels as it
has been reported that such structures contain cellular en-
zymes and ribosomal RNA (Rott and Schafer 1961). Thus,
these membranous structures can cause difficulties to achieve
the depletion of cellular protein and nucleic acid contaminants
which is crucial for the downstream processing of cell culture-
based influenza vaccines. Furthermore, noninfectious parti-
cles have been described to possess certain biological activi-
ties (Brooke 2014; Marcus et al. 2009) and their production in
the late phase of infection can affect the efficacy and quality of
live-attenuated vaccines even more dramatically. Hence, opti-
mization of the harvesting time point should be performed
carefully taking the characteristics of noninfectious particles
into account.
Our analysis of the intracellular dynamics of influenza vi-
rus replication shows that the synthesis of all three viral RNA
species occurs early during the infection and levels out already
at 4 hpi (Fig 3). This raises the question why viral RNA syn-
thesis shuts down so early and whether a prolonged phase of
viral RNA synthesis would lead to higher cell-specific virus
yields. Two influenza virus proteins have been reported to
inhibit viral RNA synthesis, i.e., M1 and NEP. It was recog-
nized early that the M1 protein inhibits influenza virus poly-
































































Fig. 5 Evaluation of cell cycle and infection status. MDCK cells were
infected with the influenza PR8 virus at an MOI of 0.1. Infection and cell
cycle analysis were performed using imaging flow cytometry by staining
for vRNPs and DAPI, respectively. a Comparison of the fraction of
infected cells in the total population and in each cell cycle phase. b
Proportion of infected cells in the different cell cycle phases. c
Percentage of non-infected cells in the different cell cycle phases in
mock cultures
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matrix proteins of other negative-strand RNA viruses
(reviewed by Kranzusch and Whelan (2012)). However, it
was shown recently that NEP constitutes an additional regu-
lator of influenza virus RNA synthesis (reviewed by Paterson
and Fodor (2012)). In particular, NEP recruits M1 to vRNPs,
contributes to the shutdown of RNA synthesis, and enables
the nuclear export of vRNPs (Brunotte et al. 2014). We could
show by imaging cytometry that M1 accumulates in the nu-
cleus (Fig. 4c) at the same time when viral RNA synthesis
decreases (Fig. 3). However, it is not clear yet if viral RNA
synthesis decreases due to the binding of M1 and/or NEP to
vRNPs or due to M1 and/or NEP-mediated nuclear export of
viral genomes, which removes the template for mRNA and
cRNA synthesis. In fact, we also observed a strong export of
vRNPs from the nucleus into the cytoplasm between 3 and
4 hpi (Fig. 4c) which coincides with the decrease in viral RNA
synthesis (Fig. 3). Thus, both the accumulation of regulatory
viral proteins and the nuclear export of viral genomes might
contribute to the early shutdown of viral RNA synthesis. In
this regard, influenza virus replication might be a self-limiting
process. In particular, the accumulation of regulatory viral
proteins terminates genome replication rather early and in-
duces the transport of viral genomes towards assembly and
budding sites within the host cell. However, our results indi-
cate that additional bottlenecks at later stages of the influenza
life cycle exist which might limit the release of progeny virus.
On the one hand, we found a relatively long period in which
cells release virus particles with a constant rate (Fig. 1c). On
the other hand, we observed an accumulation of vRNPs in the
proximity of the plasma membrane (Fig. 4a). Thus, the nucle-
ar export of viral genomes occurs already early during the
infection cycle but the release of virions, which requires trans-
port of viral proteins and genomes to the plasma membrane,
virus assembly, and budding, seems to comprise unknown rate
limiting steps.
It has been reported by others that the influenza virus pref-
erentially infects human H292 lung epithelial cells in the G1
phase (Ueda et al. 2013). In contrast, our infection of aMDCK
cell population at lowMOI showed no preferential infection in
any cell cycle stage (Fig. 5). Ueda et al. used the same influ-
enza virus strain (PR8) but cell lines differed which might
explain contradictory results. In addition, the experimental
setup was different since they used a single-virus infection
system. For human A549 cells, it has been shown that influ-
enza virus infections cause a cell cycle arrest in the G0/G1
phase and cells synchronized in the G0/G1 phase showed in-
creased viral protein expression as well as higher progeny
virus production (He et al. 2010). In MDCK cells, we did
not find higher viral protein expression of cells in the G0/G1
phase based on the fluorescent intensity of the imaging flow
cytometry measurement (data not shown). Furthermore, no
cell cycle arrest in the early phase of the infection up to 9 h
was observed (Fig. 5b, c). Unfortunately, we were not able to
analyze later time points since we found secondary infections
at 12 hpi even in the absence of trypsin. However, the result
that the cell cycle stage has no impact on influenza virus
replication in MDCK cells is in line with our previous obser-
vation that the cell-specific virus yield does not correlate to the
cell size while cell size itself is typically correlated to the cell
cycle stage (Heldt et al. 2015).
In conclusion, the systematic analysis of the influenza virus
propagation in cell culture identified two stages of the virus
replication that might limit cell-specific virus yields in vaccine
manufacturing. On the one hand, our results suggest that in-
fluenza virus replication is a self-limiting process. In particu-
lar, the shutdown of viral genome replication and the transport
of viral genomes towards assembly and budding sites is in-
duced very early during the infection cycle. However, a
prolonged viral RNA synthesis might lead to higher virus
yields. This replication strategy might be disadvantageous in
nature as influenza viruses have to outrun the host immune
response, but could be superior in the artificial setting of cell
culture-based virus production. On the other hand, additional
bottlenecks seem to exist in the late phase of the viral life cycle
since progeny virus release occurs at a rather constant rate for
a relatively long period until cells become apoptotic.
Eventually, the identification of rate-limiting steps during in-
fluenza virus replication might not only support the optimiza-
tion of vaccine manufacturing but also provides promising
targets for the development of new antivirals.
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